BioCryst Pharmaceuticals Inc. (BCRX)

2.50
NASDAQ : Health Technology
Prev Close 2.57
Day Low/High 2.49 / 2.68
52 Wk Low/High 2.54 / 9.95
Avg Volume 1.81M
Exchange NASDAQ
Shares Outstanding 110.44M
Market Cap 283.83M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)
BioCryst, AgFeed: Early Volume Plays

BioCryst, AgFeed: Early Volume Plays

Several stocks trading near $5 were poised to move on above-average volume during Wednesday's session.

Biotech News on Cusp of J.P. Morgan Confab: BioBuzz

Biotech News on Cusp of J.P. Morgan Confab: BioBuzz

The J.P. Morgan Healthcare Conference kicks off with a flurry of biotech company updates.

Biotech Stock Mailbag: Novelos Therapeutics

Biotech columnist Adam Feuerstein rolls out the year's first Mailbag, answering questions about Novelos and other stocks.

Thomson, AuthenTec: Early Volume Plays

Several stocks trading near $5 were poised to move on above-average volume during Monday's session.

Incyte Licenses Drug to Eli Lilly

Rheumatoid arthritis drug is in phase II clinical studies.

Pfizer Licenses Athersys Stem Cell Drug: BioBuzz

The pharma giant will develop the drug for inflammatory bowel disease.

Biotech Stock Mailbag: Year in Review

Biotech Stock Mailbag: Year in Review

Biotech stock watchdog Adam Feuerstein looks back at the best and worst of Mailbag 2009.

BioCryst Shorts Start to Cover: BioBuzz

BioCryst Shorts Start to Cover: BioBuzz

BioCryst's fall brings profit taking, while a frustrated bull starts issuing his own press releases.

Cell Therapeutics on Dilution Watch: BioBuzz

Cell Therapeutics on Dilution Watch: BioBuzz

CEO spotted in New York with bankers in tow, looking at his wallet.

Ariad, Cephalon Make ASH Splash: BioBuzz

Ariad, Cephalon Make ASH Splash: BioBuzz

News and highlights from the American Society of Hematology annual meeting.

Hemispherx CEO Buys After Stock Collapse: BioBuzz

Hemispherx CEO Buys After Stock Collapse: BioBuzz

Carter's stock purchase hardly instills confidence in Hemispherx's future.

Slowing Swine Bursts BioCryst Bubble: BioBuzz

Slowing Swine Bursts BioCryst Bubble: BioBuzz

New study concludes H1N1 activity may not be any worse than seasonal flu.

'Mad Money Lightning Round': Stick With JPMorgan

'Mad Money Lightning Round': Stick With JPMorgan

Cramer says it's the best-run and best-capitalized company.

Cramer's 'Mad Money' Recap: Amazon's Amazing Run (Final)

Cramer's 'Mad Money' Recap: Amazon's Amazing Run (Final)

Cramer says the stock of the Internet retail giant could top $216 next year.

Cel-Sci's History of Disappearing Drugs: BioBuzz

Will Cel-Sci's flu drug last longer than its other fly-by-night projects?

BioCryst Bull Blames Conspiracy for Stock's Fall: BioBuzz

BioCryst Bull Blames Conspiracy for Stock's Fall: BioBuzz

Hedge funds, Wall Street, SEC and FDA out to hurt maker of flu drug, newsletter writer claims.

U.S. Sees Low Demand for BioCryst Flu Drug

U.S. Sees Low Demand for BioCryst Flu Drug

Peaking flu season could mean no need for further peramivir orders.

Keep an Eye on the Dollar

A number of technical developments in the greenback warrant some scrutiny.

Oculus, Bianco and Cel-Sci Oh My!: BioBuzz

Some Friday Fall tidbits from the biotech stock world.

BioCryst Competition for IV Flu Drug: BioBuzz

U.S. government orders IV versions of two flu drugs to treat hospitalized patients.

BioCryst Winners and Losers: BioBuzz

Sorting out the latest salvo in the H1N1 investor war

'Fast Money' Portfolios of the Week

'Fast Money' Portfolios of the Week

Here's what the 'Fast Money' crew's been talking about lately.

Cel-Sci's Lawyer Speaks: BioBuzz

Cel-Sci's Lawyer Speaks: BioBuzz

Cel-Sci's complaint avoids the central issue about its mystery South African partner.

BioCryst Ships Flu Drug to U.S. Government: BioBuzz

Initial order lower than expected but priced higher

Study: Cholesterol Drugs May Improve Flu Survival

Cholesterol-lowering statin drugs like Lipitor, Zocor, may improve flu survival, study finds

BioCryst 3Q Loss Grows As Peramivir Tests Continue

BioCryst 3Q Loss Grows As Peramivir Tests Continue

BioCryst takes bigger 3Q loss after starting late-stage tests of IV flu treatment peramivir

US Keeps Tight Rein on Biocryst Flu Drug

Details emerge on emergency use of peramivir for H1N1 patients.

KBR, RadioShack, WebMD Health Are Big Movers

KBR, RadioShack, WebMD Health Are Big Movers

KBR, RadioShack, WebMD Health, Sohu.com are among big market movers Monday

Premarket Roundup: BioCryst, Netflix

Premarket Roundup: BioCryst, Netflix

Premarket roundup: BioCryst jumps on FDA approval, analyst: gains from Netflix-Sony deal murky

Ahead Of The Bell: BioCryst Shares Rise On FDA Nod

Ahead Of The Bell: BioCryst Shares Rise On FDA Nod

BioCryst shares rise; FDA OKs emergency use of experimental drug peramivir to treat swine flu

TheStreet Quant Rating: D- (Sell)